Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.

July 25, 2025

Vol.51 No.29

In Brief

University of Illinois Cancer Center awarded $709,000 from DOD breast cancer research program

University of Illinois Cancer Center investigators won a $709,000 grant award from the U.S. Department of Defense Breast Cancer Research Program.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Ohio State launches pancreatic cancer trial via telehealth

The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Pre-clinical study finds link between metabolism and protective effect of breastfeeding against breast cancer

A mother’s mitochondria determines if lactation is protective or not against breast cancer—and points to a possible intervention to increase the benefit to more women, according to a pre-clinical study conducted by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

July 18, 2025

Vol.51 No.28

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

University of Illinois Cancer Center awarded $709,000 from DOD breast cancer research program

Ohio State launches pancreatic cancer trial via telehealth

Pre-clinical study finds link between metabolism and protective effect of breastfeeding against breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login